FDA Week - 05/29/2020

FDA, Industry Ponder Future Of Remote Clinical Trial Visits, Monitoring

By Beth Wang / May 27, 2020 at 2:14 PM
FDA and the pharmaceutical industry need to start thinking about what the new normal for clinical trials will be post-COVID-19, especially as continued social distancing restrictions reinforce the need for remote health care, representatives from FDA and Amgen say. Going forward, the clinical research community will need to ensure equal access to trials for all participants, especially with regard to technology, and figure out how to obtain informed consent in a virtual environment. The lessons learned from conducting clinical trials...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.